Navigation Links
AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Date:6/10/2009

ix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first multi-center efficacy study for which patient recruitment was completed in April 2008, is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include changes in sexual function. Other important endpoints include plasma changes in levels of testosterone, and assessment of other adverse events.

The third study in the Phase 3 program, a multi-center safety study, for which patient recrui
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
2. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
3. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
4. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
5. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
6. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
7. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
8. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
9. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
10. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
11. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 Patheon ... manufacturing services to the global pharmaceutical industry, will host ... Novel Approaches to Testing” on Tuesday, June 4, 2013 ... pharmaceutical manufacturers are required to comply with regulations for ... practices with limited scientific underpinning and little evaluation of ...
(Date:5/23/2013)... 23, 2013 PI’s new LPS-24 ... provide 15 mm travel range with closed-loop sensor ... dimensions make these new positioners the ideal choice ... vacuum rated version is also available. , ... datasheets can be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 ...
(Date:5/23/2013)... 23, 2013 BioTrends Research Group, one ... for specialized biopharmaceutical issues, finds that, unaided, one ... specialists reported that in the past six months, ... treatment) in anticipation of the next generation of ... when only 6 percent reported that they had ...
(Date:5/23/2013)... May 23, 2013 The New Jersey ... industries, Black Data Processing Associates (BDPA), is hosting its ... 8, 2013. This all-day event will encourage students and ... the ins and outs from many of the industries’ ... at the New Jersey Institute of Technology, the event ...
Breaking Biology Technology:Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2
... tactics. However, there is one area where I finally decided it's ... sure, there are various articles and such that describe the "improved ... The problem is that at least half of us use no ... to prove my point. I took my laptop home from work, ...
... colony of human embryonic stem cells grown over a period ... feeder cells. The cell nuclei are stained green; the cell ... Madison, Wis. Tackling a pressing and controversial ... Research Institute and the University of Wisconsin-Madison have crafted a ...
... duking it out with Los Angeles for second place in ... Chicago's business community is finite. , ,In Milwaukee and throughout ... therefore follows that the technology business community is even smaller. ... curse. , ,One of the inevitable outcomes of spending some ...
Cached Biology Technology:Screen-door security: most wireless networks left wide open 2Screen-door security: most wireless networks left wide open 3Human stem cells stand on their own 2Human stem cells stand on their own 3How name-dropping can make interviews fail 2How name-dropping can make interviews fail 3How name-dropping can make interviews fail 4
(Date:5/23/2013)... Science , Automated conserved noncoding ... promoter evolution among grasses , Within the genome ... DNA that undergo little change in position and sequence ... any proteins. Some of these evolutionarily stable sequences, so-called ... expression of other genes or the condensation of chromosomes, ...
(Date:5/23/2013)... Health at Emory University, along with partners at ... $4 million grant over four years to establish ... Exposome Research Center: Understanding Lifetime Exposures). The grant ... the United States. , The HERCULES Center ... Health Sciences (NIEHS) of the National Institutes of ...
(Date:5/23/2013)... undergo surgery or harsh treatments because science fails ... forms of the disease. Researchers at Case Western ... developing technology that allows patients to safely choose ... or take drastic measures. , The project is ... of biomedical engineering at Case Western Reserve and ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... reporting new evidence that certain high blood pressure drugs may ... cause of vision loss in people with diabetes. The study, ... lead to new ways to prevent or treat the sight-threatening ... of Proteome Research , a monthly publication. Edward ...
... are embracing new tactics to deal with an estimated ... from being won. That,s the focus of an article ... News (C&EN) , ACS, weekly newsmagazine. Counterfeiting ploys include ... identify their products as genuine. C&EN Associate Editor ...
... shown that it is not, as has long been presumed, to ... Biomechanics, who have modelled the cohesive strength of food after a ... food to ensure it is in a firm blob and, therefore, ... Dr Roland Ennos, a biomechanic in the Faculty of Life Sciences ...
Cached Biology News:How people work ... and the fingerprint mystery 2